Silvan Tuerkcan
Stock Analyst at Citizens
(4.43)
# 358
Out of 5,182 analysts
177
Total ratings
48.55%
Success rate
22.55%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Downgrades: Market Perform | n/a | $52.94 | - | 16 | Mar 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $52.06 | +65.19% | 17 | Dec 23, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.56 | +119.30% | 5 | Nov 20, 2025 | |
| ENGN enGene Therapeutics | Maintains: Market Outperform | $18 → $21 | $6.96 | +201.72% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.20 | +59.09% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $6.30 | +26.98% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.17 | +80.77% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $0.93 | +545.37% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $9.42 | +260.93% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $29.04 | +54.96% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $44.93 | +11.28% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $7.45 | +101.34% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.69 | +62.60% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.17 | +74.08% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $14.38 | +734.49% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.90 | +794.74% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.51 | +59.36% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $13.03 | +61.17% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.01 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.00 | +50.00% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $67.25 | +316.36% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.01 | +63.49% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $52.94
Upside: -
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $52.06
Upside: +65.19%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.56
Upside: +119.30%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $6.96
Upside: +201.72%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.20
Upside: +59.09%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $6.30
Upside: +26.98%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.17
Upside: +80.77%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $0.93
Upside: +545.37%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $9.42
Upside: +260.93%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $29.04
Upside: +54.96%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.93
Upside: +11.28%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $7.45
Upside: +101.34%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.69
Upside: +62.60%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.17
Upside: +74.08%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $14.38
Upside: +734.49%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.90
Upside: +794.74%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.51
Upside: +59.36%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $13.03
Upside: +61.17%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.01
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.00
Upside: +50.00%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $67.25
Upside: +316.36%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.01
Upside: +63.49%